



Date: April 1, 2012

To:
Materials Licensing Branch
U.S. Nuclear Regulatory Commission
Region III,
2443 Warrenville Road, Ste 210
Lisle, IL 60532-4350


Reference: License No. 13-32556-01

Please accept this letter as our application to transfer all license activities directly to Terre Haute Regional Hospital Materials License No 13-09649-02 and terminate the above reference NRC License.

Please terminate Premier Diagnostic Imaging (PDI) Materials License 13-32556-01 once the amendment to Terre Haute Regional Hospital Materials License No 13-09649-02 adding that location is approved. The transfer of ownership to Terre Haute Regional Hospital has already been approved in amendment number 03 of PDI Materials License 13-32556-01. The Authorized Users, Radiation Safety Committee and the Radiation Safety Officer (RSO), Edward Johnston are the same on both licenses. Radioactive material will be received, used and stored in accordance with the regulations and all statements in the license application and amendment. The locations of use, facility and equipment will be as stated as in the original PDI license. The all sealed sources and radioactive material will be secured in the hot lab when not in use. All records concerning the surveillance program (surveys, wipe tests and quality control procedures) will be maintained at the facility. No changes will be made to the existing program until approved by the Radiation Safety Committee and the NRC when required by licensing conditions or regulations. Attached is a copy of Terre Haute Regional Hospital Materials License No 13-09649-02.

Should you have any questions, please contact our RSO, Edward Johnston, phone no. (812) 251-6797. E-mail address edward.johnston@hcahealthcare.com or mail to Terre Haute Regional Hospital, 3901 South 7th Street, Terre Haute, IN 47802.

Sincerely,


RSO, Edward Johnston


CEO, Mary Ann Conroy

NRC FORM 574

PAGE 1 OF 4 PAGES
Amendment No. 61

U.S. NUCLEAR REGULATORY COMMISSION
MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

0002120

577468

<p>Licensee</p> <p>1. Terre Haute Regional Hospital</p> <p>2. 3901 South 7th Street Terre Haute, IN 47802</p>	<p>In accordance with letter dated May 2, 2012,</p> <p>3. License number 13-09649-02 is amended in its entirety as follows:</p> <p>4. Expiration date June 30, 2021</p> <p>5. Docket No. 030-09540 Reference No.</p>
---	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by in 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p> <p>E. Any byproduct material permitted by 10 CFR 31.11</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources (3M Model 6D8C; AEA Technologies Model CDC T1; Best Medical International, Inc., Model 2335 and 81-01; Medi-Physics, Inc., Model 6711; Theragenics Corp. I-Seed Models AgX100 and TheraSeed 200)</p> <p>E. Prepackaged kits</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. One curie</p> <p>D. One curie</p> <p>E. 2 millcuries</p>
--	---	--

9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. In vitro studies.

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 4 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-09649-02

Docket or Reference Number
030-09540

Amendment No. 61

CONDITIONS

- 10. Licensed material shall be used only at the licensee's facilities located at 3901 South 7th Street, Terre Haute, Indiana.
- 11. The Radiation Safety Officer (RSO) for this license is Edward Johnston III.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical uses:

Authorized Users

Material and Use

Edward R. Bartley, M.D.	10 CFR 35.100, 35.200.
Jack M. Drew, M.D.	10 CFR 35.100, 35.200, and 35.300.
Eric D. Elliott, M.D.	10 CFR 35.100 and 35.200.
Steven A. Fritsch, M.D.	10 CFR 35.100 and 35.200.
John A. Morton, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Brian J. Wiegel, M.D.	10 CFR 35.100, 35.200 and 35.300.
Peter D. Arfken, M.D.	10 CFR 35.100, 35.200 and 35.300.
Homer F. Beltz, M.D.	10 CFR 35.100 and 35.200.
Theodore P. Labus, M.D.	10 CFR 35.100, 35.200 and 35.300.
Charles A. Lerner, M.D.	10 CFR 35.100 and 35.200.
Michael S. Skulski, M.D.	10 CFR 35.100 and 35.200.
Margaret Brengle, M.D.	10 CFR 35.100 and 35.200.
Jeffrey I. Reider, M.D.	10 CFR 35.100 and 35.200.
Janalyn P. Ferguson, M.D.	10 CFR 35.100 and 35.200.
Jack J. Moss, M.D.	10 CFR 35.100 and 35.200.
Lori J. Wells, M.D.	10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-09649-02

Docket or Reference Number
030-09540

Amendment No. 61

- Thomas Hagman, M.D. 10 CFR 35.100, 35.200 and 35.300.
- J. Michael Phelps, Jr. M.D. 10 CFR 35.100, 35.200 and 35.300 (for Iodine-131, oral administration of sodium Iodide-131 less than or equal to 33 millicuries):
- Timothy L. Davis, M.D. 10 CFR 35.100, 35.200 and 35.300 (limited to I-131 in quantities not to exceed 33 mCi).
- Vincent P. Mathews, M.D. 10 CFR 35.100 and 35.200.
- William E. McGraw, M.D. 10 CFR 35.100 and 35.200.
- John Mark Michael, M.D. 10 CFR 35.100, 35.200 and 35.300.
- Frank J. Pistoia, M.D. 10 CFR 35.100 and 35.200.
- Cristina N. Shinaver, M.D. 10 CFR 35.100, 35.200 and 35.300.
- Richard L. Hallet, M.D. 10 CFR 35.100, 35.200 and 35.300.
- Caryn Cockerill Anderson 10 CFR 35.100 and 35.200.
- Warren Kent Hansen, M.D. 10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide-131 less than or equal to 33 millicuries).
- Carlo Roberto Lazzaro, M.D. 10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide-131 less than or equal to 33 millicuries).
- Jane S. Mitchell, M.D. 10 CFR 35.100 and 35.200.
- David R. Gulliver, M.D. 10 CFR 35.100, 35.200 and 35.300.
- Thomas M. Schmitz, M.D. 10 CFR 35.300 and 35.400.
- Jonathan Kahn, M.D. 10 CFR 35.100, 35.200 and 35.300.
- Laura Dugan, M.D. 10 CFR 35.100 and 35.200.

- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 14. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 4 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-09649-02

Docket or Reference Number
030-09540

Amendment No. 61

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Letter dated May 2, 2011, with attached application dated May 2, 2011.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAY 03 2012

By *Toye L. Simmons*
Toye L. Simmons
Materials Licensing Branch
Region III



Date: April 2, 2012

To:

Materials Licensing Branch
U.S. Nuclear Regulatory Commission
Region III,
2443 Warrenville Road, Ste 210
Lisle, IL 60532-4350


Reference: License No. 13-09649-02


Please accept this letter as our application to amend the above reference NRC License.

Please add Premier Diagnostic Imaging (PDI), 135 East McCallister Drive, Terre Haute, IN 47802 as an authorized location to use and store radioactive materials to Terre Haute Regional Hospital Materials License No 13-09649-02. The transfer of ownership to Terre Haute Regional Hospital has already been approved in amendment number 03 of PDI Materials License 13-32556-01. The Authorized Users, Radiation Safety Committee and the Radiation Safety Officer (RSO), Edward Johnston are the same on both licenses. Radioactive material will be received, used and stored in accordance with the regulations and all statements in the license application and amendment. The locations of use, facility and equipment will be as stated as in the original PDI license. The all sealed sources and radioactive material will be secured in the hot lab when not in use. All records concerning the surveillance program (surveys, wipe tests and quality control procedures) will be maintained at the facility. No changes will be made to the existing program until approved by the Radiation Safety Committee and the NRC when required by the licensing conditions or regulations. Attached is a copy of PDI Materials License No 13-32556-01.

Should you have any questions, please contact our RSO, Edward Johnston, phone no. (812) 251-6797. E-mail address edward.johnston@hcahealthcare.com or mail to Terre Haute Regional Hospital, 3901 South 7th Street, Terre Haute, IN 47802.

Sincerely,


RSO, Edward Johnston


CEO, Mary Ann Conroy

NRC FORM 374

PAGE 1 OF 4 PAGES
Amendment No. 03

U.S. NUCLEAR REGULATORY COMMISSION
MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

EL 2200
Licensee

578159

In accordance with letter dated
August 24, 2012,
3. License number 13-32556-01 is amended in its entirety to read as follows:

- 1. Premier Diagnostic Imaging, LLC
- 2. 135 McCallister Drive
Terre Haute, IN 47802

- 4. Expiration date **March 31, 2015**
- 5. Docket No. **030-36874**
Reference No.

- | | | |
|--|--|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <ul style="list-style-type: none"> A. Any byproduct material permitted by 10 CFR 35.100. B. Any byproduct material permitted by 10 CFR 35.200. C. Iodine-131 permitted by 10 CFR 35.300. | <p>7. Chemical and/or physical form</p> <ul style="list-style-type: none"> A. Any B. Any C. Sodium Iodide | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <ul style="list-style-type: none"> A. As needed B. As needed C. As needed, not to exceed 300 millicuries of iodine-131 |
|--|--|---|

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any iodine-131 procedure permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 135 McCallister Drive, Terre Haute, Indiana.
- 11. The Radiation Safety Officer for this license is **Edward Johnston III**.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number 13-32556-01
Docket or Reference Number 030-36874
Amendment No. 03

B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Edward R. Bartley, M.D.	10 CFR 35.100 and 35.200.
Jack M. Drew, M.D.	10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).
Eric D. Elliott, M.D.	10 CFR 35.100 and 35.200.
Steven A. Fritsch, M.D.	10 CFR 35.100 and 35.200.
John A. Morton, M.D.	10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).
Brian J. Wiegel, M.D.	10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).
Peter D. Arfken, M.D.	10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).
Homer F. Beltz, M.D.	10 CFR 35.100 and 35.200.
Theodore P. Labus, M.D.	10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).
Charles A. Lerner, M.D.	10 CFR 35.100 and 35.200.
Michael S. Skulski, M.D.	10 CFR 35.100 and 35.200.
Margaret Brengle, M.D.	10 CFR 35.100 and 35.200.
Jeffrey I. Relder, M.D.	10 CFR 35.100 and 35.200.
Janalyn P. Ferguson, M.D.	10 CFR 35.100 and 35.200.
Jack J. Moss, M.D.	10 CFR 35.100 and 35.200.
Lori J. Wells, M.D.	10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-32556-01

Docket or Reference Number
030-36874

Amendment No. 03

Authorized Users

Material and Use

Thomas Hagman, M.D.

10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).

J. Michael Phelps, Jr. M.D.

10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).

Timothy L. Davis, M.D.

10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).

Vincent P. Mathews, M.D.

10 CFR 35.100 and 35.200.

William E. McGraw, M.D.

10 CFR 35.100 and 35.200.

John Mark Michael, M.D.

10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).

Frank J. Pistoia, M.D.

10 CFR 35.100 and 35.200.

Cristina N. Shinaver, M.D.

10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).

Richard L. Hallet, M.D.

10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).

Caryn Cockerill Anderson, M.D.

10 CFR 35.100 and 35.200.

Warren Kent Hansen, M.D.

10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).

Carlo Roberto Lazzaro, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide-131 less than or equal to 33 millicuries).

Jane S. Mitchell, M.D.

10 CFR 35.100 and 35.200.

David R. Gulliver, M.D.

10 CFR 35.100, 35.200, and 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 4 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-32556-01

Docket or Reference Number
030-36874

Amendment No. 03

Authorized Users

Thomas M. Schmitz, M.D.

Jonathan Kahn, M.D.

Laura Dugan, M.D.

Material and Use

10 CFR 35.300 (for Iodine-131, oral administration of sodium iodide-131 less than or equal to 33 millicuries).

10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide-131 less than or equal to 33 millicuries).

10 CFR 35.100 and 35.200.

- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.28.4. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application dated February 2, 2005; and
 - B. Letters dated July 15, 2005, May 22, 2008, August 24, 2012, and November 2, 2012.

For the U.S. Nuclear Regulatory Commission

Date NOV 13 2012

By Joye L. Simmons
Joye L. Simmons
Materials Licensing Branch
Region III

FAX

Dr. Thomas Schmitz
Siebenmorgen Cancer Center Radiation Oncology
TERRE HAUTE REGIONAL HOSPITAL
 3901 South Seventh Street
 Terre Haute, IN 47802
 Phone: 812-237-1630
 Fax: 812-237-9572

FACSIMILE TRANSMITTAL SHEET

Date: _____ 4/11/13
 To: _____ NRC
 FAX: _____ 630-515-1078
 From: _____ Michelle

TOTAL NUMBER OF PAGES (including cover sheet): 110

MESSAGE: _____

CONFIDENTIALITY NOTICE: The information contained in the facsimile transmission is confidential. This information is intended for the exclusive use of the individuals or entities named above. If you are not the intended recipient, you are hereby notified that any disclosure or dissemination to anyone other than the individuals or entities named above is strictly prohibited. You are further advised that any use or copying of this information by an unauthorized recipient be strictly prohibited. If you have received this information in error, please immediately notify the sender by telephone to arrange for the return or destruction of the transmitted documents.